The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatments using live bacteria.
T3 Pharmaceuticals was founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz and Helmut Kessmann as a spin-off of the University of Basel. The team has developed an efficient protein delivery technology that is based on the use of live bacteria. While the technology has diverse applications in research, T3 Pharma has further developed the system to serve as a novel therapeutic to treat solid tumors.
Chief Executive Officer, completed a PhD on microbial pathogenesis at the University of Basel in the framework of the Werner Siemens Excellence fellowships. He started working on the T3 Pharma technology during his Post-doctoral studies at the Biozentrum. For this achievements he received the Novartis and University of Basel Excellence Scholarship in 2014 and a research price from the Huggenberger-Bischoff foundation for cancer research in the same year.
Chief Scientific Officer, holds a PhD in cell biology from the University of Basel, which he performed in the framework of the Werner Siemens Excellence fellowships. He acquired profound knowledge in host-microbe interactions and inflammation signaling. Christoph has hands-on experience in high-throughput screening and is skilled in automated image analysis.
Executive director microbiology at T3 Pharma, she holds a PhD in microbiology from the University of Basel. Marlise has more than ten years hands-on experience in molecular microbiology and co-authored several scientific publications on the bacterial type three secretion system.
Designated board member, he is an entrepreneur and successful Business / Corporate Development Executive in Biotech, with two decades international experience. He demonstrated history of successful leadership in emerging companies with cutting edge technologies and highly innovative products in areas of great unmet medical need.
Helmut is co-founder of two Biotech companies which both developed to IPO and beyond (Disovery Partners, IPO at NasdaQ in 2000; Santhera, IPO at SIX in 2006). He has a strong track record of successful negotiation and deal making with extensive experience in technology, development stage and product focussed transactions across many therapeutic areas world-wide. These deals included many in- and outlicensing deals, MBOs and several M&As.
Prior to that he held research management positions at Ciba-Geigy, now Novartis. Helmut studied biology, philosophy and business administration and completed his PhD in biochemistry in 1988 at the University Münster, Germany.
Director and Professor at the Biozentrum, University of Basel and former director at the Max-Planck-Institute for Biochemistry in Martinsried, Germany. He is a leader in the field of cell cycle and cancer and one of Europe’s top cited cell biologists.
He has a longstanding track record in the field of tumor biology and translational cancer research. In particular, he has developed and tested various anti-angiogenic agents for cancer therapy, he has generated a variety of preclinical cancer models to study the molecular mechanisms underlying malignant tumor progression and to experimentally test novel therapeutic regimen in a preclinical setting, and he has discovered several novel molecular pathways and master switches critical for the metastatic dissemination of malignant cancer cells.
Professor emeritus at the Biozentrum, University of Basel and Professor at the University of Namur, Belgium. As a co-discoverer of the bacterial type 3 secretion system, he has more than 30 years of experience on the pathogenesis of Yersinia enterocolitica and other Gram-negative bacteria. He is a renowned expert in the field of bacterial pathogenesis and highly cited author of many research publications.